AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01047943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical application of STA-21 ointment for treatment of psoriasis
Study NCT01629706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
Study NCT01629706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renu multi-purpose solution
Description: Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
Study NCT02059642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG01CI (1400 mg)
Description: MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
Study NCT02059642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 1400 mg administered orally once daily
Study NCT02207101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E-OJ-01 (OXYJUN)
Study NCT02207101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05943990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3845097
Description: GSK3845097 was administered.
Study NCT05943990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered as lymphodepleting chemotherapy.
Study NCT04724174 — intervention group
Intervention type: PROCEDURE
Intervention: pancreaticogastrostomy
Description: Pancreaticogastrostomy technique was performed according to the precise description of Addeo et al.
Study NCT04724174 — intervention group
Intervention type: PROCEDURE
Intervention: pancreaticojejunostomy
Description: Pancreaticojejunostomy technique was performed using the 5/0 polypropylene interrupted monofilament suture in a one-layered duct-to-mucosa end-to-side anastomosis (Cattell-Warren anastomosis).
Study NCT05943990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine was administered as lymphodepleting chemotherapy.
Study NCT03508700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL 5.6 mg
Description: cyclobenzaprine HCl sublingual tablets
Study NCT03278340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safe Workplaces - Technology
Description: After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
Study NCT04422821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring
Description: Flash Glucose Monitoring FreeStyle Libre™ (Abbott Diabetes Care, Alameda, CA) sensor placed subcutaneously that will be applied for 14 days, then removed and changed for the second sensor for the next 14 days.
Study NCT02987673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MGB/OAGB
Study NCT02987673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG
Study NCT01553539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic angiotensin-(1-7)
Description: Given SC
Study NCT01553539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT01659944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: Capsules for oral administration
Study NCT01659944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Tablets for oral administration
Study NCT00514449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
Study NCT00514449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
Study NCT01651260 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental ET Tube Securement Device
Description: Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
Study NCT01463852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
Study NCT00170157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given orally
Study NCT00170157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given orally
Study NCT03278340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sun Safe Workplaces -In Person
Description: After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
Study NCT01629706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearCare
Description: Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
Study NCT01629706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual lens care
Description: Lens care per habitual use
Study NCT02117414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan sequences of the head and chest regions
Description: Non-diagnostic MRI scans
Study NCT00170157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Given orally
Study NCT00170157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Given orally
Study NCT00170157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT00170157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT00170157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT00170157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT00170157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative study
Study NCT00170157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative study
Study NCT03078673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training intervention, motor skill training
Description: cross country specific motor skill strength training
Study NCT03078673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training intervention, maximal strength training
Description: general maximal strength training
Study NCT03078673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: regular training
Study NCT00805883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Phothtermal Ablation
Description: Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
Study NCT01832311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
Study NCT02595060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled molgramostim (rhGM-CSF)
Study NCT02595060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled placebo
Description: formulated as the active substance without molgramostim
Study NCT03184701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
Study NCT02540174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: integrated addiction treatment program
Description: At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program.
Study NCT02540174 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard of care
Description: The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~* At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~* At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption
Study NCT00003530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT03837756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT02117414 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Waiting Period Visit
Description: Waiting period time will equate to 1 hour
Study NCT01546064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Choledocho-choledochostomy with T-tube
Description: In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
Study NCT01546064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Choledocho-choledochostomy without T-tube
Description: The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
Study NCT03158714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Connecting Mindfully
Study NCT03158714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELEVATE
Study NCT02537574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX/BUP
Description: Daily doses
Study NCT02537574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTX/PBO-B
Description: Daily doses
Study NCT02537574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PBO-N/PBO-B
Description: Daily doses
Study NCT04161300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam Rolling (FR)
Description: FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.
Study NCT04161300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (CG)
Description: The CG did not receive any intervention.
Study NCT04161300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthopaedic Manual Physical Therapy Group (OMPT)
Description: Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
Study NCT02663687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 esterase inhibitor
Description: Subjects will receive escalating doses I-IV as both IV and SC injections
Study NCT02663687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo
Study NCT02663687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP623
Description: SHP623
Study NCT02663687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04661553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mueller's polarimetric colposcopy Group 1
Description: Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation.
Study NCT02375815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin Choice Implementation
Study NCT03849846 — intervention group
Intervention type: OTHER
Intervention: Focus groups
Description: Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
Study NCT04584073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application
Description: Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
Study NCT04422821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-Monitoring of Blood Glucose
Description: Self-Monitoring of Blood Glucose with a standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) performed through a skin-puncturing 4 times a day for 28 days.
Study NCT04313530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.
Study NCT04313530 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.
Study NCT00415493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold-dry air provocation
Description: 15 minute exposure to cold-dry air by nasal mask
Study NCT00415493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-moist air provocation
Description: 15 minute exposure to warm-moist air by nasal mask
Study NCT00262743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day~Phase II: 2000 mg orally twice a day
Study NCT03379233 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Concept2 inhaler
Description: Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler
Study NCT03379233 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concept2 inhaler with patient application
Description: Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler with application used for monitoring
Study NCT00965484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Genotropin Pen
Description: Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
Study NCT00315211 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Topotecan
Description: Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
Study NCT00315211 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Docetaxel
Description: Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle
Study NCT00848211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection on Day 0, Day 28, and Day 84
Study NCT00848211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (0.03mg)
Description: Subcutaneous injection on Day 0, Day 28, and Day 84
Study NCT00848211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (0.1mg)
Description: Subcutaneous injection on Day 0, Day 28, and Day 84
Study NCT00848211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (0.6mg)
Description: Subcutaneous injection on Day 0, Day 28, and Day 84
Study NCT00419003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: anticonvulsant medication
Study NCT00419003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: subanesthetic dose of NMDAR antagonist
Study NCT00419003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: subanesthetic dose of NMDAR antagonist
Study NCT00419003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: glutamate release inhibitor
Study NCT00419003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: glutamate release inhibitor
Study NCT00125775 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Engerix-B at 0, 1, 6 months
Study NCT03837756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT00646867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrix
Description: Twice daily topical application
Study NCT00646867 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily topical application
Study NCT00217100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: 1 tablet a day